TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02566460

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Resuscitation
Description: First, either crystalloid or colloid could be given to achieve a CVP of 8 to 12 mm Hg. Second, if the mean arterial pressure (MAP) was less than 65 mm Hg, norepinephrine was administrated to maintain MAP ≥65 mm Hg. If the mean arterial pressure was higher than 90 mm Hg, vasodilators were given until it was 90 mm Hg or below. Finally, SCVO2 or lactate clearance will be checked to determine red blood cells transfused or not to achieve a haematocrit of at least 30%. If ScvO2 or lactate clearance remains unmet target value, dobutamine could be used in the treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resuscitation
Description: First, either crystalloid or colloid could be given to achieve a CVP of 8 to 12 mm Hg. Second, if the mean arterial pressure (MAP) was less than 65 mm Hg, norepinephrine was administrated to maintain MAP ≥65 mm Hg. If the mean arterial pressure was higher than 90 mm Hg, vasodilators were given until it was 90 mm Hg or below. Finally, SCVO2 or lactate clearance will be checked to determine red blood cells transfused or not to achieve a haematocrit of at least 30%. If ScvO2 or lactate clearance remains unmet target value, dobutamine could be used in the treatment.
Study: NCT01905631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aurstat Anti-Itch Hydrogel (Aurstat)
Description: Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
Study: NCT02008552

Intervention type: GENETIC
Group type: OTHER
Intervention: Sampling of blood
Description: Sampling of blood was taken and analyse to research factor genetic
Study: NCT00840762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VircoType HIV-1 genotypic interpretation
Description: VircoType HIV-1 genotypic interpretation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local Expert Review of HIV Genotypic resistance testing
Description: Local Expert Review of HIV Genotypic resistance testing
Study: NCT00363428

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: exercise intervention
Description: life style

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: life style

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: smoking cessation intervention
Description: Life style

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation intervention
Description: Life style

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: counseling intervention
Description: life style

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: life style

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: educational intervention
Description: life style

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: life style

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional surgery
Description: life style

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: life style

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: pulmonary complications management/prevention
Description: life style

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary complications management/prevention
Description: life style
Study: NCT03965507

Intervention type: OTHER
Intervention: Evaluation of the prevalence of sacroiliac joint dysfunction in lumbar disc herniation

Intervention type: OTHER
Intervention: Evaluation of the prevalence of sacroiliac joint dysfunction in lumbar disc herniation
Study: NCT01884909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate ER Tablet 200 mg
Description: 1 \* 200 mg tablet per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate ER Tablet 200 mg
Description: 1 \* 200 mg tablet per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 'TOPROL-XL®' ER Tablets 200 mg
Description: 1 \* 200 mg tablet per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 'TOPROL-XL®' ER Tablets 200 mg
Description: 1 \* 200 mg tablet per day
Study: NCT03669952

Intervention type: OTHER
Intervention: None intervention
Description: No interventions are realized, only observational study
Study: NCT03934242

Intervention type: OTHER
Intervention: Questionnaire on new born's bedding
Description: Questionnaire on new born's bedding (Child's position in the bed : dorsal, ventral or lateral, presence of pillow or stuffed in bed, presence of coverage and presence of the bed sharing) at two times (during hospitalisation and one month later)

Intervention type: OTHER
Intervention: Questionnaire on new born's bedding
Description: Questionnaire on new born's bedding (Child's position in the bed : dorsal, ventral or lateral, presence of pillow or stuffed in bed, presence of coverage and presence of the bed sharing) at two times (during hospitalisation and one month later)
Study: NCT02190968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Depression Care
Description: Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR\*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Depression Care
Description: Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR\*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
Study: NCT00589108

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray
Description: Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray
Description: Sigma Pressfit Condylar Posterior Cruciate Substituting System (fixed bearing with an all polyethylene tray)
Study: NCT04366648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK-1201I
Description: malignant solid tumor that has been confirmed by histopathology and/or cytology

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK-1201I
Description: malignant solid tumor that has been confirmed by histopathology and/or cytology
Study: NCT00839488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: famotidine 20 mg iv
Description: famotidine 20 mg q12h
Study: NCT01138202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: LPV/r 400/100 mg BID + 2 NRTI for arm 1 (total 48 weeks) LPV/r 600/150 mg BID + 2 NRTI for arm 2 (total 48 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: LPV/r 400/100 mg BID + 2 NRTI for arm 1 (total 48 weeks) LPV/r 600/150 mg BID + 2 NRTI for arm 2 (total 48 weeks)
Study: NCT01151124

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX0E03 neural stem cells
Description: Single administration by surgical delivery to the damaged area of the brain
Study: NCT02502786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanized anti-GD2 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Study: NCT03685331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Combination of palbociclib, olaparib, and fulvestrant.
Study: NCT02190968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Mood Balance
Description: Mindful Mood Balance is an individually tailored, web-based version of Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2002) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participated in 8 internet sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
Study: NCT01810575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WC3036-11F/Alprostadil in Vehicle 2.5%
Description: 330 mcg alprostadil in 2.5% vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WC3036-12F/Alprostadil in Vehicle 0.5%
Description: 330 mcg alprostadil in 0.5% vehicle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WC3036-13P/Vehicle Only 0.5%
Description: 100 mg cream vehicle 0.5%.
Study: NCT03685331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Combination of palbociclib, olaparib, and fulvestrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Combination of palbociclib, olaparib, and fulvestrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Combination of palbociclib, olaparib, and fulvestrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Combination of palbociclib, olaparib, and fulvestrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Combination of palbociclib, olaparib, and fulvestrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Combination of palbociclib, olaparib, and fulvestrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Combination of palbociclib, olaparib, and fulvestrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Combination of palbociclib, olaparib, and fulvestrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Combination of palbociclib, olaparib, and fulvestrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Combination of palbociclib, olaparib, and fulvestrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Combination of palbociclib, olaparib, and fulvestrant.
Study: NCT01285765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCHOP21
Description: Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RCHOP21
Description: Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13
Study: NCT02920268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance and yoga intervention
Study: NCT00071812

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Description: Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 4 mg/kg
Description: Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Description: Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.
Study: NCT02534792

Intervention type: OTHER
Intervention: Revalvulation

Intervention type: OTHER
Intervention: Revalvulation
Study: NCT01296724

Intervention type: OTHER
Group type: OTHER
Intervention: Measure of intravesical pressure
Description: For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various Intravesical pressure measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.

Intervention type: OTHER
Group type: OTHER
Intervention: Measure of intravesical pressure
Description: For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various IVP measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
Study: NCT03913143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sepofarsen
Description: RNA antisense oligonucleotide for intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sepofarsen
Description: RNA antisense oligonucleotide for intravitreal injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham-Procedure (no experimental drug administered)
Study: NCT03344185

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Glycaemic Diet
Description: This intervention consisted of three low GI meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Glycaemic Diet
Description: This intervention consisted of three meals, all with a high GI value.
Study: NCT04527081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0302-COVID19
Description: 2.0 mg of AG0302-COVID19 twice at 2-week intervals
Study: NCT01187615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed
Description: In Part A of this trial, regorafenib will be administered in a sequential dosing with a seven day wash out period before the next infusion of pemetrexed and cisplatin. Regorafenib will be administered at a dose of 160 mg qd from Day 2 to Day 14 followed by a 7 days break. Pharmacokinetics of regorafenib will be assessed on Day 14 of Cycle 1 and Day 1 of Cycle 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed
Description: In Part B of this trial, regorafenib will be administered continuously from Day 1 to Day 21. Only in Cycle 1, regorafenib dosing will start on Day 2 in order to assess the pharmacokinetics of pemetrexed and cisplatin without concomitant regorafenib dosing. Pharmacokinetics of regorafenib will be assessed on Day 21 of Cycle 1 and on Day 1 of Cycle 2.
Study: NCT04527081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0302-COVID19
Description: 2.0 mg of AG0302-COVID19 twice at 4-week intervals
Study: NCT04491773

Intervention type: DRUG
Intervention: Tadalafil 20 MG
Description: To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, for more than 6 months.
Study: NCT01202344

Intervention type: OTHER
Group type: OTHER
Intervention: Additional x-ray images
Description: Approximately 3 additional x-ray images following angioplasty (within 1 hour)

Intervention type: OTHER
Group type: OTHER
Intervention: Additional x-ray images
Description: Approximately 3 additional x-ray images following angioplasty (within 1 hour)
Study: NCT01157065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-78898A
Description: Investigational treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Anti-vascular endothelial growth factor (VEGF) treatment
Study: NCT04527081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0302-COVID19
Description: 2.0 mg of AG0302-COVID19 three times at 2-week intervals
Study: NCT01982422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Food, Nutrient-Dense Dietary Intervention
Description: The dietary intervention will be a whole food, nutrient-dense diet which restricts processed foods high in food additives while optimizing micronutrient intake.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Normal standard-of-care for pregnancy.
Study: NCT01973634

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)
Description: Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
Description: Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
Description: Minimal surgical margin \< 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
Description: Minimal surgical margin \< 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
Study: NCT01015846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Redcord (sling exercise) and traditional exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stability exercise
Description: Traditional core stability exercise
Study: NCT00256217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg. oral every day for 2 - 4 weeks
Study: NCT02333578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma Treatment
Description: This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
Study: NCT03662100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-injector (AI)
Description: AI to administer LY3074828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-injector (AI)
Description: AI to administer LY3074828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-injector (AI)
Description: AI to administer LY3074828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled syringe (PFS)
Description: PFS to administer LY3074828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled syringe (PFS)
Description: PFS to administer LY3074828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled syringe (PFS)
Description: PFS to administer LY3074828
Study: NCT04216862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Different type of exercises for treatment of Forward Head Posture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Different type of exercises for treatment of Forward Head Posture
Study: NCT01257204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablets, oral, 0 mg, once daily, for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a
Description: Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks
Study: NCT02666235

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischaemic conditioning
Description: Intermittent inflation of an arm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a drawn curtain. The clinical team and researchers will be masked to the intervention type.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Arm cuff placement, no inflation;
Description: Sham procedure involving arm cuff placement, no inflation: A blood pressure cuff will be placed on the arm for 40 minutes. The cuff will not be inflated. The patient will be in bed behind a curtain on the cardiology ward. The curtain will obscure the patient from the attending cardiology team. The clinical team and researchers will be masked to the intervention type.